Breaking News

Societal CDMO to Support Xequel Bio’s iNexin Trials

Will provide process development and clinical trial services culminating in cGMP manufacturing of the compound and placebo for Phase 2 trials.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Societal CDMO, Inc. has been selected by Xequel Bio, Inc. to provide CDMO services to support the ongoing clinical development of a new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform. Societal CDMO will provide a range of services including process development and clinical trial services, culminating in cGMP manufacturing of the compound and placebo for upcoming Phase 2 trials of iNexin (aCT1 ophthalmic solution). iNexin is a sterile, preservative-free op...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters